Skip to main content

Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

The Original Article was published on 03 March 2020

Correction to: Intensive Care Med https://doi.org/10.1007/s00134-020-05991-x

The original version of this article unfortunately contained mistakes. There is an incorrect unit of IL-6 in Fig. 1 and Supplementary Table 1. It should be pg/mL rather than ng/mL. The corrected Fig. 1 and Supplementary Table 1 can be found below. The authors apologize for the mistakes.

Fig. 1
figure1

a Age distribution of patients with confirmed COVID-19; b key laboratory parameters for the outcomes of patients with confirmed COVID-19; c interval from onset of symptom to death of patients with confirmed COVID-19; d summary of the cause of death of 68 died patients with confirmed COVID-19

Supplementary Table 1: Summary of clinical features and laboratory results of the patients with confirmed COVID-19

  Normal Range Died
(N = 68)
Discharged
(N = 82)
p-value
Demographics     
Age, years   67 (15-81) 50 (44-81) <0.001
Sex     
Male   49 (72%) 53 (65%)  
Female   19 (28%) 29 (35%)  
Comorbidities   43 (63%) 34 (41%) 0.01
Hypertension   29 (43%) 23 (28%) 0.07
Cardiovascular disease   13 (19%) 0 <0.001
Diabetes   12 (18%) 13 (16%) 0.88
Cerebrovascular disease   7 (10%) 5 (6%) 0.49
Chronic obstructive pulmonary disease   2 (3%) 1 (1%) 0.59
Chronic kidney disease   2 (3%) 0 0.20
Malignancy   2 (3%) 1 (1%) 0.59
Chronic liver disease   1 (1%) 3 (4%) 0.63
Connective tissue disease   1 (1%) 0 0.45
Signs and Symptoms     
Fever   59 (87%) 68 (83%) 0.67
Cough   51 (75%) 59 (72%) 0.81
Sputum production   29 (43%) 25 (30%) 0.17
Fatigue   15 (22%) 22 (27%) 0.63
Myalgia   9 (13%) 10 (12%) 1
Haemoptysis   3 (4%) 0 0.09
Dyspnea   59 (87%) 51 (62%) 0.001
Respiratory failure   58 (85%) 13 (16%) <0.001
ARDS   55 (81%) 7 (9%) <0.001
Acute kidney injury   21 (31%) 2 (2%) <0.001
Infection   11 (16%) 1 (1%) 0.002
Treatments     
ICU admission   30 (44%) 11 (13%) <0.001
High flow nasal cannula   31 (46%) 10 (12%) <0.001
Non-invasive mechanical ventilation   46 (68%) 5 (6%) <0.001
Invasive mechanical ventilation   25 (37%) 0 <0.001
ECMO   7 (10%) 0 0.003
CRRT   5 (7%) 0 0.02
Prone position mechanical ventilation   3 (4%) 0 0.09
Antiviral treatment   33 (49%) 55 (67%) 0.05
Antibiotic treatment   63 (93%) 80 (98%) 0.66
Antifungal treatment   12 (18%) 5 (6%) 0.04
Glucocorticoid treatment   31 (46%) 22 (27%) 0.02
Time from onset of symptom to start of Glucocorticoid treatment, days   11.7 (6.9) 11.4 (4.4) 0.89
Time from hospital admission to start of Glucocorticoid treatment, days   1.5 (1.2) 3.2 (2.7) 0.01
Glucocorticoid treatment duration, days   7.2 (6.7) 7.0 (5.0) 0.92
Supportive therapy   45 (66%) 18 (22%) <0.001
Length of stay, days   7.4 (5.5) 12.3 (4.4) <0.001
Laboratory Findings     
Time from onset of symptom to test, days   11.6 (6.8) 9.8 (4.3) 0.07
White blood cell count, × 109/L 3.50-9.50 10.62 (4.76) 6.76 (3.49) <0.001
Lymphocyte count, × 109/L 1.10-3.20 0.60 (0.32) 1.42 (2.14) <0.001
Haemoglobin, g/L 130.0-175.0 127.0 (16.7) 127.6 (16.3) 0.82
Platelet count, × 109/L 125.0-350.0 173.6 (67.7) 222.1 (78.0) <0.001
Albumin, g/L 35.0-52.0 28.8 (3.8) 32.7 (3.8) <0.001
Alanine aminotransferase, U/L 9.0-50.0 170.8 (991.6) 48.68 (83.1) 0.35
Aspartate aminotransferase, U/L 15.0-40.0 288.9 (1875.5) 40.7 (57.8) 0.31
Total bilirubin, μmol/L 0.0-26.0 18.1 (10.7) 12.8 (6.8) 0.001
Blood urea nitrogen, mmol/L 3.1-8.0 8.65 (4.5) 5.11 (2.1) <0.001
Creatinine, umol/L 59.0-104.0 91.2 (56.2) 72.1 (22.2) 0.02
Creatine kinase, U/L 50.0-310.0 319.4 (838.5) 231.7 (862.3) 0.56
Lactate dehydrogenase, U/L 120.0-250.0 905.8 (2619.1) 297.9 (110.4) 0.08
Cardiac troponin, pg/mL 2.0-28.0 30.3 (151.0) 3.5 (6.2) <0.001
Myoglobin, ng/mL 0.0-146.9 258.9 (307.6) 77.7 (136.1) <0.001
C-reactive protein, mg/L 0.0-5.0 126.6 (106.3) 34.1 (54.5) <0.001
Interleukin-6, pg/mL 0.0-7.0 11.4 (8.5) 6.8 (3.61) <0.001
Serum ferritin, ng/mL 21.8-274.7 1297.6 (1030.9) 614.0 (752.2) <0.001
  1. Data are n (%), n/N (%), mean (SD), and median (IQR). When the data were normally distributed, continuous variables were then described using median and interquartile range (IQR) values.
  2. ARDS = acute respiratory distress syndrome. ECMO = extracorporeal membrane oxygenation. ICU = intensive care unit. CRRT = continuous renal replacement therapy.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Jianxin Song.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 21 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ruan, Q., Yang, K., Wang, W. et al. Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 46, 1294–1297 (2020). https://doi.org/10.1007/s00134-020-06028-z

Download citation